Research graph
References from Blockade of mutant RAS oncogenic signaling: A 2026 update. Local targets link to admitted publications; unresolved targets remain external evidence.
Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS
2021 · External reference
An unidentified virus which causes the rapid production of tumours in mice
10.1038/2041104b0 · 1964 · External reference
Malignant lymphomas of extrathymic origin induced in rats by murine erythroblastosis virus
1969 · External reference
RAS oncogenes: the first 30 years
10.1038/nrc1097 · 2003 · External reference
A transforming gene present in human sarcoma cell lines
10.1038/299171a0 · 1982 · External reference
Identification of transforming gene in two human sarcoma cell lines as a new member of the ras gene family located on chromosome 1
10.1038/303396a0 · 1983 · External reference
Isolation and preliminary characterization of the transforming gene of a human neuroblastoma cell line
10.1073/pnas.80.2.383 · 1983 · External reference
Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules
10.1073/pnas.81.18.5704 · 1984 · External reference
10.1016/j.csbj.2019.12.004 · 2019 · Admitted local publication
Protein prenylation: a pivotal posttranslational process
10.1016/s0006-291x(03)00323-1 · 2003 · External reference
Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins
10.1126/science.2406906 · 1990 · External reference
RAF protein-serine/threonine kinases: structure and regulation
10.1016/j.bbrc.2010.07.092 · 2010 · External reference
Targeting oncogenic Raf protein-serine/threonine kinases in human cancers
10.1016/j.phrs.2018.08.013 · 2018 · External reference
MEK1/2 dual-specificity protein kinases: structure and regulation
10.1016/j.bbrc.2011.11.145 · 2012 · External reference
Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas
10.1016/j.phrs.2016.12.009 · 2017 · External reference
ERK1/2 MAP kinases: structure, function, and regulation
10.1016/j.phrs.2012.04.005 · 2012 · External reference
Targeting ERK1/2 protein-serine/threonine kinases in human cancers
10.1016/j.phrs.2019.01.039 · 2019 · External reference
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting
10.1038/nrc3860 · 2015 · External reference
Targeting the PI3K pathway in cancer: are we making headway?
10.1038/nrclinonc.2018.28 · 2018 · External reference
Treating cancer with phosphatidylinositol-3-kinase inhibitors: increasing efficacy and overcoming resistance
10.1194/jlr.s092130 · 2019 · External reference
The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism
10.1038/s41568-019-0216-7 · 2020 · External reference
Oncogenic signaling pathways in The Cancer Genome Atlas
10.1016/j.cell.2018.03.035 · 2018 · External reference
Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies
2021 · External reference
SOS GEFs in health and disease
10.1016/j.bbcan.2020.188445 · 2020 · External reference
The ErbB/HER family of protein-tyrosine kinases and cancer
10.1016/j.phrs.2013.11.002 · 2014 · External reference
Dragging Ras back in the ring
10.1016/j.ccr.2014.02.017 · 2014 · External reference
RAS proteins and their regulators in human disease
10.1016/j.cell.2017.06.009 · 2017 · External reference
EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research
2021 · External reference
Targeting KRAS in pancreatic ductal adenocarcinoma: The long road to cure
10.3390/cancers15205015 · 2023 · External reference
The frequency of Ras mutations in cancer
10.1158/0008-5472.can-19-3682 · 2020 · External reference
Targeting KRAS for cancer therapy
10.1111/bph.70546 · 2026 · External reference
The current state of the art and future trends in RAS-targeted cancer therapies
10.1038/s41571-022-00671-9 · 2022 · External reference
Outcomes following KRASG12C inhibitor treatment in patients with KRASG12C-mutated solid tumors: A systematic review and meta-analysis
10.1016/j.phrs.2024.107060 · 2024 · External reference
Therapeutic targeting of RAS: New hope for drugging the "undruggable"
10.1016/j.bbamcr.2019.118570 · 2020 · External reference
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
10.1038/nature12796 · 2013 · External reference
Discovery of a covalent inhibitor of KRAS G12C (AMG 510) for the treatment of solid tumors
10.1021/acs.jmedchem.9b01180 · 2020 · External reference
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
10.1016/s0169-409x(00)00129-0 · 2001 · External reference
ProteinsPlus: a publicly available resource for protein structure mining
10.1093/nar/gkaf377 · 2025 · External reference
Sotorasib: First Approval
10.1007/s40265-021-01574-2 · 2021 · External reference
Health-related quality of life in patients with KRAS(G12C)-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial
10.1016/s1470-2045(25)00352-3 · 2025 · External reference
KRAS G12C Inhibition with sotorasib in advanced solid tumors
10.1056/nejmoa1917239 · 2020 · External reference
Sotorasib for lung cancers with KRAS p.G12C mutation
10.1056/nejmoa2103695 · 2021 · External reference
Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C
10.1056/nejmoa2308795 · 2023 · External reference
Targeting KRAS in solid tumors: current challenges and future opportunities of novel KRAS inhibitors
10.3390/pharmaceutics13050653 · 2021 · External reference
Adagrasib: First Approval
10.1007/s40265-023-01839-y · 2023 · External reference
Identification of the clinical development candidate MRTX849, a covalent KRASG12C inhibitor for the treatment of cancer
10.1021/acs.jmedchem.9b02052 · 2020 · External reference
Acquired resistance to KRASG12C inhibition in cancer
10.1056/nejmoa2105281 · 2021 · External reference
Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers
10.1016/j.phrs.2018.11.014 · 2019 · External reference
10.1038/d41573-026-00145-y · 2026 · Admitted local publication
Discovery of daraxonrasib (RMC-6236), a potent and orally bioavailable RAS(ON) multi-selective, noncovalent tri-complex inhibitor for the treatment of patients with multiple RAS-addicted cancers
10.1021/acs.jmedchem.4c02314 · 2025 · External reference
Conserved conformational dynamics reveal a key dynamic residue in the gatekeeper loop of human cyclophilins
10.1021/acs.jpcb.2c08650 · 2023 · External reference
Active-site residues of cyclophilin A are crucial for its incorporation into human immunodeficiency virus type 1 virions
10.1128/jvi.71.9.7110-7113.1997 · 1997 · External reference
Structure of human cyclophilin A in complex with the novel immunosuppressant sanglifehrin A at 1.6 A resolution
10.1074/jbc.m501623200 · 2005 · External reference
RMC-6236-001 Investigators, Daraxonrasib in previously treated advanced RAS-mutated pancreatic cancer
10.1056/nejmoa2505783 · 2026 · External reference
RASolute 302 Trial Investigators, Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer
10.1056/nejmoa2605555 · 2026 · External reference
Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries
2026 · External reference
PD-1/L1 immune checkpoint inhibitors for KRAS-mutant non-small cell lung cancer: a multicenter retrospective real-world study
10.1186/s12885-025-13868-9 · 2025 · External reference
Immune-based therapies in pancreatic cancer: a systematic review of ongoing clinical trials (2020-2022)
10.1007/s12029-025-01194-z · 2025 · External reference
Advancements in immunotherapy for colorectal cancer treatment: a comprehensive review of strategies, challenges, and future prospective
10.1007/s00384-024-04790-w · 2024 · External reference
Guidelines for preparing color figures for everyone including the colorblind
10.1016/j.phrs.2017.02.005 · 2017 · External reference
